EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Melanoma Clinical Decision Support System: An Artificial Intelligence-Based Tool to Diagnose and Predict Disease Outcome in Early-Stage Melanoma Patients

Jose Luis Diaz-Ramón, Jesus Gardeazabal, Rosa Maria Izu iD, Estibaliz Garrote, Javier Rasero iD, Aintzane Apraiz, Cristina Penas iD, Sandra Seijo, Cristina Lopez-Saratxaga iD, Pedro Maria De la Peña, Ana Sanchez-Diaz, Goikoane Cancho-Galan und 8 weitere

Cancers · 06.04.2023 · 15 (7) · 2174

DOI: 10.3390/cancers15072174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 06.04.2023. Verfasst von Jose Luis Diaz-Ramón und 19 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Service, Cruces University Hospital, 48903 Barakaldo, Spain. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basque Government, University of the Basque Country, European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study set out to assess the performance of an artificial intelligence (AI) algorithm based on clinical data and dermatoscopic imaging for the early diagnosis of melanoma, and its capacity to define the metastatic progression of melanoma through serological and histopathological biomarkers, enabling dermatologists to make more informed decisions about patient management. Integrated analysis of demographic data, images of the skin lesions, and serum and histopathological markers were analyzed in a group of 196 patients with melanoma. The interleukins (ILs) IL-4, IL-6, IL-10, and IL-17A as well as IFNγ (interferon), GM-CSF (granulocyte and macrophage colony-stimulating factor), TGFβ (transforming growth factor), and the protein DCD (dermcidin) were quantified in the serum of melanoma patients at the time of diagnosis, and the expression of the RKIP, PIRIN, BCL2, BCL3, MITF, and ANXA5 proteins was detected by immunohistochemistry (IHC) in melanoma biopsies. An AI algorithm was used to improve the early diagnosis of melanoma and to predict the risk of metastasis and of disease-free survival. Two models were obtained to predict metastasis (including “all patients” or only patients “at early stages of melanoma”), and a series of attributes were seen to predict the progression of metastasis: Breslow thickness, infiltrating BCL-2 expressing lymphocytes, and IL-4 and IL-6 serum levels. Importantly, a decrease in serum GM-CSF seems to be a marker of poor prognosis in patients with early-stage melanomas.

Schlagwörter

Stichwörter der Autor:innen

artificial intelligencebiomarkersdeep learningdiagnosisdisease-freemachine learningmelanomametastasisprognosisrisk factors

Autor:innen und Institutionen

  • Dermatology Service, Cruces University Hospital, 48903 Barakaldo, Spain.
  • Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
  • Dermatology Service, Basurto University Hospital, 48013 Bilbao, Spain.
  • TECNALIA, Basque Research and Technology Alliance (BRTA), 20850 Gipuzkoa, Spain.
  • Department of Cell Biology and Histology, University of the Basque Country/EHU, 48940 Leioa, Spain.
  • Department of Psychology, Carnegie Mellon University, Pittsburgh, PA 15213, USA.

ORCID-Profile: Rosa Maria Izu, Javier Rasero, Cristina Penas, Cristina Lopez-Saratxaga, Arrate Sevilla, Jesus María Cortes, Santos Alonso, Aintzane Asumendi, María Dolores Boyano

Förderung

  • Basque Government
  • University of the Basque Country
  • European Commission
  • Ministry of Economy, Industry and Competitiveness
  • UPV/EHU
  • H2020-ESCEL JTI
  • MINECO

Zitieren

APA

Diaz-Ramón, J. L., Gardeazabal, J., Izu, R. M., Garrote, E., Rasero, J., Apraiz, A., Penas, C., Seijo, S., Lopez-Saratxaga, C., De la Peña, P. M., Sanchez-Diaz, A., Cancho-Galan, G., Velasco, V., Sevilla, A., Fernandez, D., Cuenca, I., Cortes, J. M., Alonso, S., Asumendi, A., & Boyano, M. D. (2023). Melanoma Clinical Decision Support System: An Artificial Intelligence-Based Tool to Diagnose and Predict Disease Outcome in Early-Stage Melanoma Patients. Cancers, 15(7), 2174. https://doi.org/10.3390/cancers15072174

Vancouver

Diaz-Ramón JL, Gardeazabal J, Izu RM, Garrote E, Rasero J, Apraiz A, et al. Melanoma Clinical Decision Support System: An Artificial Intelligence-Based Tool to Diagnose and Predict Disease Outcome in Early-Stage Melanoma Patients. Cancers. 2023;15(7):2174. doi:10.3390/cancers15072174

BibTeX
@article{DiazRamn2023,
  author = {Diaz-Ramón, Jose Luis and Gardeazabal, Jesus and Izu, Rosa Maria and Garrote, Estibaliz and Rasero, Javier and Apraiz, Aintzane and Penas, Cristina and Seijo, Sandra and Lopez-Saratxaga, Cristina and De la Peña, Pedro Maria and Sanchez-Diaz, Ana and Cancho-Galan, Goikoane and Velasco, Veronica and Sevilla, Arrate and Fernandez, David and Cuenca, Iciar and Cortes, Jesus María and Alonso, Santos and Asumendi, Aintzane and Boyano, María Dolores},
  title = {Melanoma Clinical Decision Support System: An Artificial Intelligence-Based Tool to Diagnose and Predict Disease Outcome in Early-Stage Melanoma Patients},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {7},
  pages = {2174},
  doi = {10.3390/cancers15072174}
}
Kostenlos starten →